Latest news with #ShaneStorey
Business Insider
6 days ago
- Business
- Business Insider
Wilsons Sticks to Their Buy Rating for EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR)
Wilsons analyst Shane Storey maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report) yesterday and set a price target of A$3.00. The company's shares opened today at A$1.09. Confident Investing Starts Here: Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Monash IVF Group Ltd, and EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. According to TipRanks, Storey has an average return of 7.5% and a 50.62% success rate on recommended stocks. EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an analyst consensus of Strong Buy, with a price target consensus of A$2.80, implying a 156.88% upside from current levels. In a report released on May 25, Bell Potter also maintained a Buy rating on the stock with a A$2.25 price target. The company has a one-year high of A$2.08 and a one-year low of A$0.82. Currently, EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an average volume of 1.08M.
Business Insider
12-05-2025
- Business
- Business Insider
Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Wilsons analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals (TLPPF – Research Report) on May 8 and set a price target of A$35.00. The company's shares closed last Friday at $17.88. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Nanosonics Limited, and Opthea . According to TipRanks, Storey has an average return of 9.9% and a 53.46% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $21.77 average price target, representing a 21.79% upside. In a report released on April 29, Bell Potter also maintained a Buy rating on the stock with a A$34.00 price target. The company has a one-year high of $24.85 and a one-year low of $9.60. Currently, Telix Pharmaceuticals has an average volume of 7,300.
